Stance of MRD in Non-Hodgkin ’s Lymphoma and its upsurge in the novel era of cell-free DNA

AbstractCancer genomics has evolved over the years from understanding the pathogenesis of cancer to screening the future possibilities of cancer occurrence. Understanding the genetic profile of tumors holds a prognostic as well as a predictive value in this era of therapeutic surveillance, molecular remission, and precision medicine. Identifying molecular markers in tumors is the current standard of approach, and requires an efficient combination of an accessible sample type and a profoundly sensitive technique. Liquid biopsy or cell-free DNA has evolved as a novel sample type with promising results in recent years. Although cell-free DNA has significant role in various cancer types, this review focuses on its application in Non-Hodgkin ’s Lymphoma. Beginning with the current concept and clinical relevance of minimal residual disease in Non-Hodgkin’s lymphoma, we discuss the literature on circulating DNA and its evolving application in the realm of cutting-edge technology.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Title: What Is Non-Hodgkin's Lymphoma?Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 10/6/2021 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news
AbstractHealth-related quality of life (HRQoL) is a multidimensional concept including physical, emotional, social, and cognitive functions, disease symptoms, and side effects of treatment. Differences in HRQoL due to gender, existence of comorbidities, and number of chemotherapy cycles are little explored in diffuse large B-cell lymphoma (DLBCL) survivors. Our objective was to investigate whether differences in HRQoL in function of these factors exist 1 year after the diagnosis of DLBCL. One hundred and one patients, enrolled in the RT3 (Real-Time Tailored Therapy) Study, answered self-administrated European Organization ...
Source: Annals of Hematology - Category: Hematology Source Type: research
This article presents a review of Hodgkin lymphoma and non-Hodgkin lymphoma. These two common haematology diagnoses are frequently suspected by GPs and non-cancer professionals, and subsequently treated by haematologists and chemotherapy outpatient departments across the country. It is therefore important for all health professionals, including nurses in all settings, to be aware of the main characteristics of both of these lymphomas. There are strong similarities and striking differences between the disease processes, the presenting symptoms, prognostics and treatment pathways. The age of presentation in each is markedly ...
Source: British Journal of Nursing - Category: Nursing Authors: Source Type: research
CONCLUSION: Approximately 11% of patients with FA and 14% of patients with AT develop cancer by age 18 years.PMID:34597127 | DOI:10.1200/JCO.21.01495
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Background: Cutaneous T-cell lymphomas (CTCL) are a rare group of non-Hodgkin lymphomas that present in skin. The most studied subtypes, mycosis fungoides (MF) and S ézary syndrome (SS), together represent around two-thirds of all cases. MF/SS disease staging is multi-compartmental utilising a modified TNMB classification. Leukemic involvement in MF/SS has previously been found to be an independent prognostic factor affecting overall survival, disease-specific survival and increasing risk of disease progression (Agar 2010, Am Soc J Clin Oncol), although further research is ongoing.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTER PRESENTATIONS: QUALITY OF LIFE Source Type: research
Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma characterized by malignant skin-homing T cells with an increasing bias towards the T helper cell type 2 (Th2) during disease progression. Patients with advance CTCL have a high disease burden and the majority of CTCL patients suffer from severe itching (pruritus). A key challenge in the treatment of advanced CTCL is to maintain and to stabilize initial therapeutic responses after systemic treatment. Addressing this clinical need, the oral class I, IIb, IV HDAC inhibitor resminostat is currently under clinical evaluation for disease control after systemic therapy (R...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTER PRESENTATIONS: BIOLOGIC INSIGHTS Source Type: research
Prolonged complete remissions (CRs) are rare in advanced-stage cutaneous T-cell lymphomas (CTCLs). Ifosfamide + etoposide (I+E) have been used to treat lymphomas, combined with platinum-based agents in Hodgkin disease or non-Hodgkin lymphomas including peripheral T-cell lymphomas. Monoclonal antibodies have induced long-term remissions in CTCL but are usually poorly effective in transformed disease Allogeneic haematopoietic stem cell transplantation (alloHSCT) holds a potential for cure but relies on the existence of a pretransplant CR, which may require the use of chemotherapeutic regimens.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: ORAL PRESENTATIONS: TREATMENTS Source Type: research
li Fabiana V. Mello Patrícia F. R. Siqueira Patrícia Moura Francisco Nicanor Macedo Danielle N. Forny Luíza Simião Ana Luíza Pureza Marcelo Gerardin Poirot Land Carlos Eduardo Pedreira Jacques J. M. van van Dongen Alberto Orfao Elaine Sobral da da Costa Early diagnosis of pediatric cancer is key for adequate patient management and improved outcome. Although multiparameter flow cytometry (MFC) has proven of great utility in the diagnosis and classification of hematologic malignancies, its application to non-hematopoietic pediatric tumors remains limited. Here we...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Clin Radiol. 2021 Sep 25:S0009-9260(21)00425-6. doi: 10.1016/j.crad.2021.09.002. Online ahead of print.ABSTRACTBreast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare but emerging T-cell non-Hodgkin lymphoma. It has two distinct subtypes, "effusion-only" or "mass-forming" disease, arising around implants in patients with in situ or previous history of textured-surface breast implants. The clinical, histopathological and imaging features are unique and nuanced as compared to primary breast malignancy and other lymphoma categories. Prompt recognition and diagnosis triggers referral t...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Hodgkin's Disease | Lymphoma